Axos Financial에 대한 매도 수량은 투자자에게 Axos Financial의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Axos Financial (NYSE:AX) 주식, 공매도 수량 보고

Axos Financial

Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment . The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.

Axos Financial Inc

HSBC BANK 13/11/24 WNT

AXIOS SUSTANBLE GRWTH A by AXIOS Sustainable Growth Acquisition Corporation

AXIOS Sustainable Growth Acquisition Corp

AXA SA

AXA ORD

Abraxas Petroleum Corp

AXIS BANK GDR

AXIS BANK 144A GDR

AXIS BANK LTD S/GDR 144A by Axis Bank Ltd.

Axis Bank Ltd

AXIOS MOBILE ASSETS ORD by Axios Mobile Assets Corp.

EYES ON THE GO INC by Eyes on the Go, Inc.

Eyes on the Go Inc

ALLIXON INTL CORP by Allixon International Corp.

Allixon International Corp

AZUCAR MINERALS LTD by Azucar Minerals Ltd.

Azucar Minerals Ltd

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics Inc

ISH ACTAXEE ETF

AXEL

Axfood AB

AXIS ENERGY CORP by Axis Energy Corporation

Axis Energy Corp

Accent Group Ltd

Axogen Inc

ALEXIUM INTL GRP LTD ORD by Alexium International Group Ltd.

Alexium International Group Ltd

AXIL Brands Inc

AXIM BIOTECHNOLOGIES INC by Axim Biotechnologies, Inc.

AXIM Biotechnologies Inc

AXIS Token

American Axle & Manufacturing Holdings, Inc. Common Stock

American Axle & Mfg Holdings Inc

Axelar - United States Dollar

Axiologix Inc

AXMIN Inc

AXM PHARMA INC by AXM Pharma, Inc.

ALLIANCE NICKEL LTD by ALLIANCE NICKEL LTD

Alliance Nickel Ltd

AXION VENTURES INC by Axion Ventures Inc.

Axion Ventures Inc

Axonics Inc

Axon Enterprise Inc

American Express Co

AXPR

AXIS PETROLEUM CO CAP by Axis Petroleum Co.

AXION POWER INTL INC by Axion Power International, Inc.

Axion Power International Inc

AMERICAN EXPRESS ORD

Amrep Corp

AMARC RESOURCE LTD by Amarc Resources Ltd.

Amarc Resources Ltd

Amexdrug Corp

Axis Capital Holdings Limited Common Stock

Axis Capital Holdings Ltd

Axie Infinity - United States Dollar

Axsome Therapeutics Inc

Axis Capital Holdings Limited Depositary Shares, each representing 1/100th interest in a share of a 5.50% Series E Preferred Shares

Axalta Coating Systems Ltd. Common Shares

Axalta Coating Systems Ltd

AXALTA COATING SYSTEMS ORD

AXIS TECHS GROUP INC by Axis Technologies Group, Inc.

Axis Technologies Group Inc

AXT Inc

AXTEL SAB DE CV B by Axtel S. A.. B. De CV

Axtel SAB de CV

CDN MAVERICK CAP CORP by CDN MAVERICK CAP CORP.

CDN Maverick Capital Corp

Exxe Group Inc

ALDERON IRON ORE CORP by Alderon Iron Ore Corp.

Alderon Iron Ore Corp

Axiata Group Bhd

Indaptus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces compelling safety, pharmacokinetics, and biomarker data on its lead compound, Decoy20, at the Society for Immunotherapy of Cancer (SITC) 2024 annual meeting. The data derive from two cohorts (13 patients) of Decoy20 single administration and one cohort (6 patients) of Decoy20 weekly administration in the Company's ongoing Phase 1 clinical trial. The SITC conference is being held November 6-10, 2024 in Houston, Tex.
The data presented demonstrated that Decoy20 administered intravenously once weekly mainly showed side effects that were classified as mild or moderate and transient in duration. Further, pharmacokinetic analysis confirmed that Decoy20 quickly disappeared from the bloodstream after administration, supporting the Company's "pulse" approach. One patient in the trial who has squamous cell carcinoma of the head and neck (SCCHN) with high levels of PD-L1, which is a protein that is associated with tumor response to certain immunotherapies, had "stable disease" — meaning the cancer had not progressed or worsened — at the time of their first imaging scan.

Biotech

News

General

INDP

Indaptus Therapeutics Presents Encouraging Interim Safety Data From Phase 1 Clinical Trial Of Decoy20 At The Society For Immunotherapy Of Cancer 2024 Annual Meeting

WIIM

Texas Pacific Land shares are trading lower after the company reported a year-over-year decrease in Q3 EPS results and worse-than-expected Q3 sales results.

HC Wainwright &amp; Co. analyst Ed Arce reiterates Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) with a Buy and maintains $75 price target.

Price Target

Reiteration

Analyst Ratings

ALGS

HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $75 Price Target

Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) reported quarterly earnings of $2.54 per share which beat the analyst consensus estimate of $2.41 by 5.39 percent. The company reported quarterly sales of $1.726 billion which beat the analyst consensus estimate of $1.677 billion by 2.90 percent. This is a 5.70 percent increase over sales of $1.633 billion the same period last year.

Earnings

Earnings Beats

Ralph Lauren Q2 2025 Adj. EPS $2.54 Beats $2.41 Estimate, Sales $1.726B Beat $1.677B Estimate

LiveOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVO#NASDAQ">LVO</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. This is a 77.78 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $32.59 million which missed the analyst consensus estimate of $33.70 million by 3.28 percent. This is a 14.25 percent increase over sales of $28.53 million the same period last year.

LiveOne Q2 2025 GAAP EPS $(0.02) Misses $(0.01) Estimate, Sales $32.59M Miss $33.70M Estimate

IHRT

iHeartMedia Q3 Sales $1.008B Beat $1.001B Estimate

Nano is Successfully Executing a Disciplined and Focused Value Creation Strategy to Drive Value for ALL Shareholders
Murchinson's Self-Serving Campaign is an Attempt to Take Control of Nano Through a Series of Proposals that Would Paralyze the Company's Strategy
Nano Urges Shareholders to Protect Their Investment and Vote "FOR" Nano's Proposals
Act Fast – Voting Cut-Off Sunday, December 1st, 2024, at 11:59 p.m. ET
To Learn More Visit: <a href="https://www.globenewswire.com/Tracker?data=gzWXWYPEmuxT_FDF7tP29TzULnkhGWfeFdtoFYVhazjDslpMj0ldHB5pPuUy0Z_Pefk22Phd7D3wBn129zu384B-e_DkBLlWduMae9P97tunW6AyM6YxQYY-NFv0tklJ">www.ProtectingNanoValue.com</a>
Waltham, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/NNDM#NASDAQ">NNDM</a>) ("Nano" or the "Company"), a leading supplier of Additively Manufactured Electronics ("AME") and multi-dimensional polymer, metal &amp; ceramic Additive Manufacturing ("AM") 3D printing solutions, today sent a letter to its shareholders in connection with the Company's upcoming 2024 Annual General Meeting of Shareholders ("the Annual Meeting"). The letter reiterates the disciplined and focused steps the Company is taking to drive value for all shareholders.
&nbsp;

NNDM

Nano Dimension Sends Letter to Shareholders; Says Murchinson's Self-Serving Campaign Is An Attempt To Take Control Of Nano Through A Series Of Proposals That Would Paralyze The Company's Strategy; Nano Urges Shareholders To Protect Their Investment And Vote "FOR" Its Proposals

Medical Properties Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.20 by 20 percent. The company reported quarterly sales of $225.827 million which missed the analyst consensus estimate of $247.230 million by 8.66 percent. This is a 26.34 percent decrease over sales of $306.576 million the same period last year.

Earnings Misses

Medical Properties Trust Q3 2024 FFO $0.16 Misses $0.20 Estimate, Sales $225.827M Miss $247.230M Estimate

Vericel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCEL#NASDAQ">VCEL</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.05) by 60 percent. This is a 75 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $57.901 million which beat the analyst consensus estimate of $55.201 million by 4.89 percent. This is a 27.03 percent increase over sales of $45.581 million the same period last year.

VCEL

Vericel Q3 2024 GAAP EPS $(0.02) Beats $(0.05) Estimate, Sales $57.901M Beat $55.201M Estimate

Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and maintains $28 price target.

ACAD

Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $28 Price Target

Chicago Atlantic Admin acted as administrative agent on the funding of a $30 million senior secured credit facility for Deep Roots Holdings, a vertically integrated cannabis operator in Nevada. Deep Roots Holdings has a standalone cultivation and processing facility in the Silver State, runs five dispensaries and plans to open one more in Dec. 2024.
"Deep Roots is a company to watch in 2025, and it's our pleasure to take a front-row seat and support their growing investment portfolio," stated David Kite, managing partner at Chicago Atlantic. "Their team has shown operational expertise at every level, exceptional business acumen and a strong balance sheet – We couldn't be more excited to partner with them."
The capital provided by Chicago Atlantic, on behalf of its affiliated investment funds, will support Deep Roots Harvest's expansion as it takes on additional retail and cultivation assets across Nevada. In October 2024, Deep Roots Harvest <a href="https://www.benzinga.com/markets/cannabis/24/04/38450434/deep-roots-harvest-to-acquire-the-source-operation-in-nevada">acquired most of the asset</a>s of Nevada cannabis operator The Source Holdings, LLC, including four retail operations, two provisional retail licenses and one operating facility for cultivation.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41765421/south-dakota-rejects-measure-29-cannabis-legalization-fails-again">South Dakota Rejects Measure 29: Cannabis Legalization Fails Again</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
The successful move positions Deep Roots to operate 12 total dispensaries and establishes them as the market share leader in Nevada.
Keith Capurro, CEO of Deep Roots Harvest, said the company will continue its strategic growth in 2025 and beyond.
"Chicago Atlantic has quickly proven themselves as a valuable partner as we continue to invest across our portfolio of businesses," said Capurro. "With a larger balance sheet and meaningful additional borrowing capacity, we are well positioned to execute on our broader strategy."
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/23/07/33098371/chicago-firm-sees-value-in-ny-rec-market-speeds-up-roll-out-with-150m-investment">Chicago Firm Sees Value In NY Rec Market, Speeds Up Roll-Out With $150M Investment</a></li>
</ul>
Photo: Courtesy of Deep Roots Harvest via Business Wire

Cannabis

Cannabis Operator Deep Roots Harvest Secures $30M From Chicago Atlantic To Expand Across Nevada

Health Care

ADPT

Adaptive Biotechnologies Announced That Palmetto GBA, A Medicare Administrative Contractor, Has Expanded Coverage Of clonoSEQ To Include Detection And Monitoring Of Measurable Residual Disease In Medicare Patients With Mantle Cell Lymphoma

NewAmsterdam Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $35.0, a high estimate of $37.00, and a low estimate of $31.00. This current average reflects an increase of 0.95% from the previous average price target of $34.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1730984473_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive NewAmsterdam Pharma. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$36.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to NewAmsterdam Pharma. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of NewAmsterdam Pharma compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of NewAmsterdam Pharma's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of NewAmsterdam Pharma's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NAMS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on NewAmsterdam Pharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into NewAmsterdam Pharma's Background</h2>
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
<h3>Financial Milestones: NewAmsterdam Pharma's Journey</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: NewAmsterdam Pharma displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 32.73%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1711.58%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): NewAmsterdam Pharma's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -9.76%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): NewAmsterdam Pharma's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -8.34%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: NewAmsterdam Pharma's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NAMS

What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma

Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $62.5, a high estimate of $70.00, and a low estimate of $55.00. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1730984463_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Ionis Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ionis Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Ionis Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Ionis Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IONS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ionis Pharmaceuticals analyst ratings.</a>
<h2>About Ionis Pharmaceuticals</h2>
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
<h3>Key Indicators: Ionis Pharmaceuticals's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Ionis Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 19.55%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ionis Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -29.42% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Ionis Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -23.66%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Ionis Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.43%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Ionis Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 5.47. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IONS

Where Ionis Pharmaceuticals Stands With Analysts

5 analysts have expressed a variety of opinions on Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $17.4, a high estimate of $20.00, and a low estimate of $15.00. This current average has increased by 0.87% from the previous average price target of $17.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1730984454_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Amicus Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Dennis Ding</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Amicus Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Amicus Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Amicus Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Amicus Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FOLD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amicus Therapeutics analyst ratings.</a>
<h2>Discovering Amicus Therapeutics: A Closer Look</h2>
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
<h3>Financial Insights: Amicus Therapeutics</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Amicus Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 34.04% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Amicus Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -12.39%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Amicus Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -11.93%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Amicus Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.13%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Amicus Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 3.35. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FOLD

Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights

During the last three months, 8 analysts shared their evaluations of Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $145.75, a high estimate of $160.00, and a low estimate of $126.00. Observing a 4.64% increase, the current average has risen from the previous average price target of $139.29. 
<img src="https://www.benzinga.com/files/images/story/2024/1730984442_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Sun Communities by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wesley Golladay</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$126.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$150.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Peter Abramowitz</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$160.00</td>
<td>-</td>
</tr>
<tr>
<td>James Feldman</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$154.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$149.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Wesley Golladay</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$144.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$138.00</td>
<td>$127.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sun Communities. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sun Communities compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Sun Communities's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Sun Communities's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SUI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sun Communities analyst ratings.</a>
<h2>All You Need to Know About Sun Communities</h2>
Sun Communities is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently owns a portfolio of 666 properties, which includes 350 manufactured housing communities, 179 residential vehicle communities, and 137 marina properties. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.
<h3>Key Indicators: Sun Communities's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Sun Communities displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 1.09%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Sun Communities's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 6.03%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Sun Communities's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.75%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Sun Communities's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.3%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.14.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 8 Ratings For Sun Communities

Across the recent three months, 6 analysts have shared their insights on Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $92.0, a high estimate of $120.00, and a low estimate of $76.00. This current average has increased by 18.86% from the previous average price target of $77.40. 
<img src="https://www.benzinga.com/files/images/story/2024/1730984429_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Q2 Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$93.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Andrew Schmidt</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$76.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Michael Del Grosso</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Buy</td>
<td>$91.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Q2 Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Q2 Holdings compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Q2 Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Q2 Holdings's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/QTWO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Q2 Holdings analyst ratings.</a>
<h2>Discovering Q2 Holdings: A Closer Look</h2>
Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.
<h3>Q2 Holdings: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Q2 Holdings showcased positive performance, achieving a revenue growth rate of 11.88% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Q2 Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.55% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Q2 Holdings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -2.76%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Q2 Holdings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.05%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 1.13, Q2 Holdings faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

QTWO

Unveiling 6 Analyst Insights On Q2 Holdings

Ratings for MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $259.75, a high estimate of $325.00, and a low estimate of $185.00. Witnessing a positive shift, the current average has risen by 8.0% from the previous average price target of $240.50.
<img src="https://www.benzinga.com/files/images/story/2024/1730984418_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive MarketAxess Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$314.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$265.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$268.00</td>
<td>$237.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Eli Abboud</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$185.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$233.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$223.00</td>
<td>$218.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to MarketAxess Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of MarketAxess Holdings compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MarketAxess Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MKTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MarketAxess Holdings analyst ratings.</a>
<h2>Delving into MarketAxess Holdings's Background</h2>
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Borse Group in 2020 adding to its product offerings.
<h3>MarketAxess Holdings's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: MarketAxess Holdings displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 9.91%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: MarketAxess Holdings's net margin is impressive, surpassing industry averages. With a net margin of 32.85%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): MarketAxess Holdings's ROE stands out, surpassing industry averages. With an impressive ROE of 4.91%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): MarketAxess Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.41% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: MarketAxess Holdings's debt-to-equity ratio is below the industry average at 0.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MKTX

Cracking The Code: Understanding Analyst Reviews For MarketAxess Holdings

B of A Securities analyst Ken Hoexter upgrades Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) from Underperform to Buy and raises the price target from $27 to $34.

Upgrades

SNDR

B of A Securities Upgrades Schneider National to Buy, Raises Price Target to $34

Needham analyst Mayank Tandon maintains Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) with a Buy and raises the price target from $90 to $120.

Needham Maintains Buy on Q2 Holdings, Raises Price Target to $120

Reports Q1 NII $292.05M, up 38.3% y/y. "Net interest income increased by 12.3% and 38.3% linked-quarter and year-over-year, respectively, driven by...

Axos Financial reports Q3 EPS $1.96, consensus $1.78

"Net interest income increased by 12.3% and 38.3% linked-quarter and year-over-year, respectively, driven by further expansion in our net interest ...

Axos Financial reports Q1 adjusted EPS $1.96, consensus $1.78

Axos Financial Non-GAAP EPS of $1.96 beats by $0.18, revenue of $320.66M beats by $22.03M

Axos Financial, Inc. (AX) Q1 2025 Earnings Call Transcript

Axos Financial, Inc. 2025 Q1 - Results - Earnings Call Presentation

Axos Financial ( ($AX) ) has realeased its Q1 earnings. Here is a breakdown of the information Axos Financial presented to its investors. Axos Fina...

Axos Financial Reports Strong Q1 2025 Earnings

Analyst Kyle Peterson of Needham reiterated a Buy rating on Axos Financial (AX – Research Report), boosting the price target to $85.00. Kyle Peters...

Axos Financial's Strong Q1 2025 Performance and Growth Prospects Lead to Buy Rating

Axos Clearing partners with Envestnet to deliver managed account solutions

Gator Capital Management Q3 2024 Investor Letter

Axos Financial ( ($AX) ) has provided an announcement. Axos Financial, Inc. is positioning itself as a formidable player in the financial markets w...

Comments

Axos Financial

매도 수량

Axos Financial (NYSE:AX) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌